Trial Profile
A multicenter, retrospective study to compare the efficacy of abatacept and tumor necrosis factor inhibitors (TNFi) in Japanese rheumatoid arthritis patients switching from tocilizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2015
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 29 Jul 2015 New trial record
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.